Product Information

Property	Description
Product Name	Mouse LXRα Recombinant Monoclonal Antibody
Antibody ID	MM0004
Target Protein	Oxysterols receptor LXR-alpha (LXRα / NR1H3)
UniProt Accession	Q9Z0Y9
Antibody Type	Recombinant monoclonal antibody
Host Species	Mouse
Recombinant Format	Full-length mouse IgG1
Isotype	Mouse IgG1
Species Reactivity	Mouse validated only
Tested Applications	WB, ELISA
Recommended Dilution for WB	1:500–1:5000
Antigen	Recombinant epitope-Fc fusion protein
Epitope Sequence	SPDSATELWKTEPQDAGDQ
Expression System	HEK293 cells
Purification	Protein G affinity chromatography
Conjugate	Unconjugated
Concentration	0.1 mg/mL
Molecular Weight	50.4 kDa
Storage Buffer	0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7
Storage Condition	Store at -20°C
Research Use	For research use only. Not for diagnostic or therapeutic applications.

Product Background

Liver X receptor alpha (LXRα, NR1H3) is a ligand-activated nuclear receptor involved in cholesterol metabolism, lipid homeostasis, inflammatory signaling, and metabolic regulation. LXRα is widely studied in liver biology, lipid metabolism, cardiovascular disease, and inflammatory signaling pathways. Mouse LXRα models are frequently used in metabolism and translational research.

Antibody Development

MM0004 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the target epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.

The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.

Binding and specificity were evaluated by:

• ELISA using recombinant epitope-Fc fusion antigen
• Western blot using recombinant MBP-epitope fusion protein
• Western blot detection of endogenous mouse LXRα protein in mammalian tissue lysates

Validation Data

ELISA Validation

ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.

Validation conditions:

• Well 1: Fc control protein
• Well 2: epitope-Fc fusion protein
• Detection substrate: TMB

Note: ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length LXRα protein binding in solution has not been tested by ELISA.

Western Blot Validation – Recombinant Fusion Protein

Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while no significant binding was observed against MBP control protein.

Validation conditions:

• Lane 1: MBP control protein
• Lane 2: MBP-epitope fusion protein
• Standard reducing Western blot

Western Blot Validation – Endogenous Full-Length Protein

Western blot analysis detected endogenous mouse LXRα protein under reducing conditions.

Validated samples:

• Mouse liver
• Mouse intestine
• eWAT

Detection condition:

• Standard reducing Western blot
• HRP-conjugated anti-mouse secondary antibody